Table 1 Changes of pulmonary function before and after treatment with tofacitinib for 6Â months
From: Treatment of MDA5-positive dermatomyositis complicated by gangrenous cholecystitis with tofacitinib
Variable | Before | After | ||
|---|---|---|---|---|
Absolute | % of predicted | Absolute | % of predicted | |
FVC (L) | 1.37 | 49 | 1.21 | 44 |
TLC (L) | 1.09 | 27 | 1.05 | 26 |
FEV1 (L) | 1.08 | 51 | 1.05 | 51 |
FEV1/FVCmix (%) | 79 | 104 | 87 | 115 |
Peak flow (L/s) | 3.44 | 64 | 3.31 | 62 |
DLCOcSB (mmol/min/kPa) | 4.2 | 22 | 12.9 | 65 |
TLCOc/VA (mmol/min/kPa/L) | 3.85 | 95 | 12.29 | 309 |